Apex Healthcare Berhad

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022

In its 2023 reporting, Apex Healthcare Berhad disclosed greenhouse gas emissions of 9.9K tCO2e/year. By scope: Scope 1: 90.9 tCO2e/year; Scope 2: 9.8K tCO2e/year; Scope 3: 1.8K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
9.9K tCO2e/year
2023
💧
Water Usage
109.6 ML/year
2023
♻️
Waste
251.0 tons/year
2023
⚙️
Energy Use
61.3K GJ/year (Non-renewable) 3461 GJ/year (Renewable)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).90.9 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.9.8K tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).1.8K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20239.9K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Achieve ISO 14001:2015 certification by 2025.
  • Implement a comprehensive monthly effluent sampling program.

📅 Medium-term

  • Achieve ISO 45001:2018 certification by 2024.
  • Increase renewable energy usage.

🔭 Long-term

  • Become a leading global pharmaceutical group in the ASEAN region.

🌱 ESG Focus Areas

Halal CertificationSustainabilityRenewable EnergyEmployee Well-beingDigitalizationSupply Chain ManagementData Privacy and SecurityResponsible Product and Marketing PracticesClimate Management and ResilienceEnvironmental Impact ManagementHealth and SafetyEmployee ManagementCommunity/SocietyEthical Business Practices

⚠️ Challenges & Risks +

  • Inflation, heightened operating costs, and geopolitical tensions.
  • Slowing economic growth and persistent inflation affecting operating costs.
  • Increased volatility in the pharmaceutical market in the latter half of 2023.
  • Raw material prices remained above pre-Covid levels and were impacted by geopolitical concerns.
  • Supply chain disruptions due to the Russia-Ukraine and Israel-Gaza conflicts.
  • Depreciation of the ringgit escalating costs for imported ingredients.
  • Risks associated with reliance on revenue contributions from key external principals.
  • Potential for unanticipated global product safety alerts and recalls.

📋 Report Information

Reporting Period: 2023
Frameworks: Bursa Malaysia Sustainability Reporting Guide (3rd Edition), GRI Standards